Candida auris outbreak: Mortality, interventions and cost of sustaining control

  25 September 2019

34 patients acquired the organism including 8 with blood stream infections. Clinical infection was significantly associated with prolonged hospital stay, haemodialysis and antifungal therapy. Variable susceptibility to amphotericin and the triazoles was seen and isolates clustered with the South Asian strains. No significant difference was detected in the survival probabilities of C .auris BSI compared to other candidemias. Outbreak control cost in excess of £ 1 million and £58,000/month during the subsequent year.

Effective Surveillance  


Unrestricted financial support by:

Antimicrobial Resistance Fighter Coalition


JSS University

Technology Database

Display your AMR Technology, Product and Service

Suppliers and Users of Technologies, Products and Services benefit from CAPI.
CAPI (Continuous AMR Partnering Initiative) unites Suppliers and Users worldwide with the aim to add to the curbing of AMR.

Read more and make your own Technology Page >>
What is going on with AMR?
Stay tuned with remarkable global AMR news and developments!